the acorda therapeutics ( na ) therapeutics program is a new technology that is a powerful tool for the treatment of patients with Parkinson's disease. it is a novel and effective drug that is a highly effective and safe drug for the treatment of patients with Parkinson 'd disease. we report the first quarter of our research and its success in the last year. we are now in a position to create substantial near and long - term value with the potential of approval of this technology in the united states. we expect to build further value with the potential approval of this new drug in european and we plan to develop additional therapeutics that harness the power of the arcus pulmonary drug delivery technology.